AnaptysBio’s trial saw 69% of its rheumatoid arthritis patients treated with rosnilimab achieve low disease activity by week ...

SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...

Shares of AnaptysBio (NASDAQ:ANAB) climbed ~12% in the premarket on Wednesday after the biotech said its lead asset, rosnilimab, reached the main goals in a mid-stage trial targeted at the autoimmune ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

Rheumatoid arthritis is a heterogeneous and progressive autoimmune disease, and patients with this condition show varied responses to treatment. Practical, reliable, individually tailored measures ...

AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

The vagus nerve, a complex bundle of 200,000 fibers connecting the brain to vital organs, has remained a medical enigma for ...

DelveInsight’s, “HDAC Inhibitor Pipeline Insight” report provides comprehensive insights about 40+ companies and 50+ pipeline ...

Patients with late-onset rheumatoid arthritis experienced greater functional impairment over 5 years, compared against those with younger-onset disease.

Higher low-carbohydrate diet (LCD) scores, characterized by reduced carbohydrate intake and increased protein consumption, are associated with a lower likelihood of rheumatoid arthritis (RA) among ...